[go: up one dir, main page]

CO2018000525A2 - Concentrado que contiene alprostadil - Google Patents

Concentrado que contiene alprostadil

Info

Publication number
CO2018000525A2
CO2018000525A2 CONC2018/0000525A CO2018000525A CO2018000525A2 CO 2018000525 A2 CO2018000525 A2 CO 2018000525A2 CO 2018000525 A CO2018000525 A CO 2018000525A CO 2018000525 A2 CO2018000525 A2 CO 2018000525A2
Authority
CO
Colombia
Prior art keywords
solvent mixture
acid
concentrate containing
water
substance
Prior art date
Application number
CONC2018/0000525A
Other languages
English (en)
Inventor
Franz Häusler
Ernst Hesse
Bernhard Hansbauer
Original Assignee
Gebro Holding Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gebro Holding Gmbh filed Critical Gebro Holding Gmbh
Publication of CO2018000525A2 publication Critical patent/CO2018000525A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición farmacéutica líquida en forma de un concentrado para la preparación de una solución para infusión, que contiene alprostadil (prostaglandina E1) como principio activo, disuelto en una mezcla de disolventes de al menos un disolvente orgánico farmacéuticamente aceptable y agua, y se caracteriza por que la proporción de agua total en la mezcla de disolventes se encuentra en el intervalo del 8 al 85 % en peso de H2O, referido a la cantidad total de la mezcla de disolventes, y por que al menos un ácido o una sustancia que actúa de ácido o de donante de protones está contenida como estabilizador para el principio activo.
CONC2018/0000525A 2015-07-27 2018-01-19 Concentrado que contiene alprostadil CO2018000525A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA50666/2015A AT518009A1 (de) 2015-07-27 2015-07-27 Konzentrat enthaltend Alprostadil
PCT/AT2016/060020 WO2017015692A1 (de) 2015-07-27 2016-07-25 Konzentrat enthaltend alprostadil

Publications (1)

Publication Number Publication Date
CO2018000525A2 true CO2018000525A2 (es) 2018-04-10

Family

ID=56852017

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0000525A CO2018000525A2 (es) 2015-07-27 2018-01-19 Concentrado que contiene alprostadil

Country Status (8)

Country Link
EP (1) EP3328358B1 (es)
AR (1) AR105504A1 (es)
AT (1) AT518009A1 (es)
BR (1) BR112018001637A2 (es)
CO (1) CO2018000525A2 (es)
MX (1) MX2018001042A (es)
PE (1) PE20180466A1 (es)
WO (1) WO2017015692A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤
US5741523A (en) * 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
DE4342232A1 (de) * 1993-12-10 1995-06-14 Hexal Pharma Gmbh Feste Zubereitung für therapeutische Zwecke mit einem Gehalt an Prostaglandin E1
CN102048687A (zh) * 2009-11-06 2011-05-11 华北制药集团制剂有限公司 一种前列地尔注射液的制备方法
CN103110579B (zh) * 2013-02-20 2014-12-10 北京德立福瑞医药科技有限公司 前列地尔注射剂

Also Published As

Publication number Publication date
WO2017015692A1 (de) 2017-02-02
EP3328358A1 (de) 2018-06-06
EP3328358B1 (de) 2022-11-23
BR112018001637A2 (pt) 2018-09-18
MX2018001042A (es) 2018-06-07
AT518009A1 (de) 2017-06-15
AR105504A1 (es) 2017-10-11
PE20180466A1 (es) 2018-03-06

Similar Documents

Publication Publication Date Title
CL2020000747A1 (es) Formulaciones de niraparib.
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
MX2016006641A (es) Composición novedosa y método de uso para controlar patógenos y prevenir enfermedades en semillas.
BR112015025172A2 (pt) composição farmacêutica
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
CO6491065A2 (es) Formulación farmacéutica
CO7111300A2 (es) Formulación de anticuerpos
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
PE20141297A1 (es) Formulaciones peptidicas robustas de liberacion controlada
DOP2015000170A (es) Compuestos químicos
CO2019012814A2 (es) Composición farmacéutica líquida estable
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
EA201791166A1 (ru) Препараты с контролируемым высвобождением
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
BR112016015190A8 (pt) Composição farmacêutica livre de antioxidante e método de preparação da mesma
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120
BR112017017643A2 (pt) formulação farmacêutica tópica
CO2018000525A2 (es) Concentrado que contiene alprostadil
AR090959A1 (es) Analogos de hexadepsipeptidos como compuestos anticancerigenos
CO2018000526A2 (es) Concentrado que contiene alprostadil
AR102248A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes